GlassScriptPhysician profile
Annette Contento
NPI 1205938701
$2,668.06
in general payments reported to CMS, 2019-2025
14 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $314 · 2021: $385 · 2022: $469 · 2023: $411 · 2024: $231 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,031.90 | 2019-2023 | |
| Abbvie INC. | $544.58 | 2022-2024 | Lumigan |
| Bausch & Lomb Americas INC. | $445.93 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Coopervision INC. | $129.18 | 2021 | |
| Alcon Vision LLC | $115.87 | 2019-2025 | Precision7 |
| Sun Pharmaceutical Industries INC. | $112.81 | 2019-2020 | |
| Oyster Point Pharma, INC. | $60.31 | 2022-2023 | Tyrvaya |
| Allergan, INC. | $59.14 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.46 | 2020 | |
| Biotissue Holdings INC. | $34.08 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $29.98 | 2024 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $22.22 | 2020 | |
| Shire North American Group INC | $21.88 | 2019 | |
| Harrow Eye, LLC | $18.72 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Contento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.